Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver.

By Shu‐hao Hsu, Bo Wang, Janaiah Kota, Jianhua Yu, S. Costinean, Huban Kutay, Lianbo Yu, Shoumei Bai, K. M. D. L. Perle, R. Chivukula and 8 more. Journal of Clinical Investigation, 2012

748 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/c4d1b215dd7859000d54e698838361dbf7db9a54

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Molecular Biology

Citations in the corpus

Development of microRNA therapeutics is coming of age (2014, neutral): “However, two recent studies reported that chronic loss of miR-122 function in Mir122 germline knockout and liver-specific knockout mice, respectively, resulted in increased incidence of steatohepatitis and hepatocellular carcinoma with age (Hsu et al , 2012; Tsai et al , 2012).”
miR-122--a key factor and therapeutic target in liver disease. (2015, background): “Furthermore, decreased miR-122 levels have been associated with poor prognosis and metastasis of liver cancer, and several targets of miR-122 have been implicated in tumourigenesis [38,43–49] (Fig.”
microRNAs in cancer (2013, background): “Several strains of mice lacking or overexpressing cancer-associated miRNAs have been developed and characterized, including the germ-line transgenic or knockout mice of miR155 (39), miR-17/92 and its paralogs (60–62), miR-21 (40), miR-221 (63), the miR-15/16-1 cluster (64), miR-122 (65, 66), and miR”
Metazoan MicroRNAs (2018, background): “miR-122 (1) miR-122 Development of fatty liver, hepatitis, fibrosis, and hepatocellular carcinoma (Hsu et al., 2012; Tsai et al., 2012); smaller hepatocytes with substantially fewer polyploid cells (Hsu et al.”